× |
|
DEXTROSE MONOHYDRATE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
DOCUSATE SODIUM Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
ENTRESTO (sacubitril; valsartan) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
SHELLAC Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
CELLULOSE, MICROCRYSTALLINE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
EGATEN (triclabendazole) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
CALCIUM SULFATE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
D&C RED NO. 28 Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
× |
|
ERLEADA (apalutamide) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
EMFLAZA (deflazacort) Drug Profile, 2024 |
$699.00 |
|
$699.00 |
× |
|
COLLOIDAL SILICON DIOXIDE Drug Excipient Business Development Opportunity Report, 2024 |
$699.00 |
|
$699.00 |
|